Literature DB >> 20659589

Role of endogenous retroviruses in murine SLE.

Lucie Baudino1, Kumiko Yoshinobu, Naoki Morito, Marie-Laure Santiago-Raber, Shozo Izui.   

Abstract

Systemic lupus erythematosus (SLE) is an autoimmune disorder characterized by B cell hyperactivity leading to the production of various autoantibodies and subsequent development of glomerulonephritis, i.e. lupus nephritis. Among the principal targets of the autoantibodies produced in murine SLE are nucleic acid-protein complexes and the envelope glycoprotein gp70 of endogenous retroviruses. Recent studies have revealed that the innate receptor TLR7 plays a pivotal role in the development of a wide variety of autoimmune responses against DNA- and RNA-containing nuclear antigens, while TLR9 rather plays a protective role. In addition, the regulation of autoimmune responses against endogenous retroviral gp70 by TLR7 suggests the implication of endogenous retroviruses in this autoimmune response. Moreover, the demonstration that TLR7 is involved in the acute phase expression of serum gp70 uncovers an additional pathogenic role of TLR7 in murine lupus nephritis by promoting the expression of nephritogenic gp70 autoantigen. Clearly, the eventual identification of endogenous retroviruses implicated in murine SLE and of mouse genes regulating their production could provide a clue for the potential role of endogenous retroviruses in human SLE.
Copyright © 2010 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20659589     DOI: 10.1016/j.autrev.2010.07.012

Source DB:  PubMed          Journal:  Autoimmun Rev        ISSN: 1568-9972            Impact factor:   9.754


  22 in total

1.  Antiviral TRIMs: friend or foe in autoimmune and autoinflammatory disease?

Authors:  Caroline Jefferies; Claire Wynne; Rowan Higgs
Journal:  Nat Rev Immunol       Date:  2011-08-25       Impact factor: 53.106

Review 2.  Immune responses to endogenous retroelements: taking the bad with the good.

Authors:  George Kassiotis; Jonathan P Stoye
Journal:  Nat Rev Immunol       Date:  2016-04       Impact factor: 53.106

3.  Translocation of a gut pathobiont drives autoimmunity in mice and humans.

Authors:  S Manfredo Vieira; M Hiltensperger; V Kumar; D Zegarra-Ruiz; C Dehner; N Khan; F R C Costa; E Tiniakou; T Greiling; W Ruff; A Barbieri; C Kriegel; S S Mehta; J R Knight; D Jain; A L Goodman; M A Kriegel
Journal:  Science       Date:  2018-03-09       Impact factor: 47.728

Review 4.  p53 in the game of transposons.

Authors:  Annika Wylie; Amanda E Jones; John M Abrams
Journal:  Bioessays       Date:  2016-09-19       Impact factor: 4.345

5.  Molecular mechanism for p202-mediated specific inhibition of AIM2 inflammasome activation.

Authors:  Qian Yin; David P Sester; Yuan Tian; Yu-Shan Hsiao; Alvin Lu; Jasmyn A Cridland; Vitaliya Sagulenko; Sara J Thygesen; Divaker Choubey; Veit Hornung; Thomas Walz; Katryn J Stacey; Hao Wu
Journal:  Cell Rep       Date:  2013-07-11       Impact factor: 9.423

Review 6.  KRAB zinc finger proteins.

Authors:  Gabriela Ecco; Michael Imbeault; Didier Trono
Journal:  Development       Date:  2017-08-01       Impact factor: 6.868

Review 7.  TLRs and interferons: a central paradigm in autoimmunity.

Authors:  Dwight H Kono; Roberto Baccala; Argyrios N Theofilopoulos
Journal:  Curr Opin Immunol       Date:  2013-11-16       Impact factor: 7.486

8.  Sarcoma Eradication by Doxorubicin and Targeted TNF Relies upon CD8+ T-cell Recognition of a Retroviral Antigen.

Authors:  Philipp Probst; Janine Kopp; Annette Oxenius; Mario P Colombo; Danilo Ritz; Tim Fugmann; Dario Neri
Journal:  Cancer Res       Date:  2017-05-08       Impact factor: 12.701

9.  Human Endogenous Retroviruses (HERVs) and Autoimmune Rheumatic Disease: Is There a Link?

Authors:  Nicola Tugnet; Paul Rylance; Denise Roden; Malgorzata Trela; Paul Nelson
Journal:  Open Rheumatol J       Date:  2013-03-22

Review 10.  Endogenous retroviruses and the development of cancer.

Authors:  George Kassiotis
Journal:  J Immunol       Date:  2014-02-15       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.